Sandoz and Polpharma Biologics have become the first companies to get FDA approval for a biosimilar of Biogen's blockbuster multiple sclerosis therapy Tysabri, after overcoming a bid by Biogen to ...

Multiple sclerosis (MS) is an inflammatory autoimmune ... Biogen’s recombinant humanized monoclonal antibody, natalizumab (TYSABRI®), mediates lymphocyte and monocyte cell adhesion and ...

Another case of a potentially fatal brain infection has been reported in a patient taking the multiple sclerosis drug Tysabri, the biotech who developed the drug announced yesterday. This is the ...

Polpharma Biologics has said it is the first company to get approval in the EU for a biosimilar version of Biogen’s blockbuster multiple sclerosis therapy Tysabri. The European Commission has ...

MS patients who achieve long-term stable disease on disease-modifying therapy may want to stop their medication for varying ...

There is currently no cure for Multiple Sclerosis (MS). Patients rarely do well with no ... Thus, drugs like natalizumab (Tysabri), fingolimod (Gilenya), and mitoxantrone (Novantrone) are typically ...

Cumulative lifetime dose limit Secondary progressive, progressive relapsing, or worsening RRMS Tysabri® Natalizumab ... Intravenous; MS: Multiple sclerosis; RRMS: Relapsing–remitting multiple ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

Researchers have made more advancements in multiple sclerosis in the last five years than in the previous 70 years. Knowing ...